Antiverse Raises $9.3M for AI Antibody Scaling

🔑 Enhanced Key Takeaways

• •Antiverse was co-founded in 2017 by CEO Murat Tunaboylu in Cardiff, UK, with offices in Boston, MA.[5][6]
• •The company previously raised £3.5M ($4.6M) in seed funding, supported by Kadmos Capital and others, to improve platform accuracy and data curation.[3][4]
• •Antiverse has partnerships with three top 20 global pharmaceutical companies and a collaboration with GlobalBio yielding two preclinical immune checkpoint inhibitors.[3][6]
• •CEO Murat Tunaboylu highlighted that one-third of FDA-approved drugs target GPCRs, yet few antibodies exist despite decades of research.[3][4]

🛠️ Technical Deep Dive

• •Platform uses target-specific libraries generated from structural and sequence data for high-confidence antibody design against GPCRs and ion channels.
• •Combines machine learning, phage display, next-generation sequencing, and advanced cell line engineering expressing millions of target receptors.
• •Generative models trained over 7 years on challenging targets enable multiparameter clustering for epitope-specific, high-affinity, and humanized antibodies.
• •In silico process outputs functional binders in 6 months by predicting sequences with high binding probability without pre-existing data.

🔮 Future ImplicationsAI analysis grounded in cited sources

⏳ Timeline